Clinical Trials
Boehringer Ingelheim closes one arm of Aptivus (tipranavir) study
Published in Hepatitis Weekly, April 3rd, 2006
The program is comprised of ongoing and planned studies in over 1000 pediatric, antiretroviral-naive, racially and gender diverse, or hepatitis co-infected patients.
Recently, Boehringer Ingelheim and the external independent Data Safety Monitoring Board (DSMB) reviewed data from one of these ongoing clinical trials, study 1182.33, which is designed to evaluate the efficacy and safety of Aptivus /ritonavir in treatment-naive HIV-infected patients. Following a thorough review of the 48-week data...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-04-03)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
HBV replication is blocked by asialoglycoprotein receptor antisense oligonucleotides - Hepatitis C Virus
Anti-hepatitis C virus responses activated by a toll-like receptor - Hepatitis C Virus
HCV infection is mediated by a pH-dependent membrane fusion process - Hepatitis C Virus
Hepatitis C virus envelope functionally analyzed by cell-cell fusion assay - Hepatitis C Virus
Novel HCV vector overcomes anti-Ad5 immunity and induces immune responses - Adverse Drug Reaction
Hemoglobin reduction is associated with the use of erythrocyte ribavirin - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
